NCT00896363 - Safety and Efficacy Study in Patients With Major Depressive Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 23, 2009

Primary Completion Date

February 9, 2010

Study Completion Date

February 9, 2010

Conditions

Depressive Disorder

Interventions

DRUG

GSK163090 1 mg

Developed for the treatment of Major Depressive Disorder

DRUG

GSK163090 Placebo

Developed for the treatment of Major Depressive Disorder

DRUG

GSK163090 3 mg

Developed for the treatment of Major Depressive Disorder

Trial Locations (15)

119992

GSK Investigational Site, Moscow

190005

GSK Investigational Site, Saint Petersburg

190121

GSK Investigational Site, Saint Petersburg

191180

GSK Investigational Site, Saint Petersburg

193167

GSK Investigational Site, Saint Petersburg

194044

GSK Investigational Site, Saint Petersburg

197341

GSK Investigational Site, Saint Petersburg

399083

GSK Investigational Site, Lipetsk Region

410060

GSK Investigational Site, Saratov

603107

GSK Investigational Site, Nizhny Novgorod

620030

GSK Investigational Site, Yekaterinburg

634014

GSK Investigational Site, Tomsk

650036

GSK Investigational Site, Kemerovo

Unknown

GSK Investigational Site, Saint Petersburg

214 019

GSK Investigational Site, Smolensk